You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Umeclidinium + Vilanterol vs Tiotropium + Olodaterol Head to Head Study

Comparative Efficacy of Once-Daily Umeclidinium + Vilanterol vs Tiotropium + Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study

Head to Head Study:

Umeclidinium + Vilanterol vs Tiotropium + Olodaterol

August 2018 – PH/UCV/0022/18 


  • These podcasts are organized and funded by GSK
  • These podcasts contain promotional content
  • No part of these podcasts can be copied or retrieved without prior written permission from GSK
  • Prescribing information may be accessed via 
  • This podcast features voice talents portraying doctors. The module and the script used were created by a GSK Medical Affairs Manager, who is employed by GSK on a full-time basis and does not hold shares in GSK.

Prescribing Information

Umeclidinium + Vilanterol (Anoro)


Full Prescribing Information available upon request .
Trademarks are owned by or licensed to the GSK group of companies 
© 2018 GSK group of companies 

Kindly forward all adverse events and product complaints to
GSK Philippines via these contact details:
Adverse events: or 0917 889 0640
 Product complaints: 0917 889 7050.